According to Neogen's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.6437. At the end of 2023 the company had a P/S ratio of 4.11.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.11 | -27.06% |
2022 | 5.63 | -34.53% |
2021 | 8.60 | -5.36% |
2020 | 9.09 | 8.49% |
2019 | 8.38 | 1.88% |
2018 | 8.22 | -3.08% |
2017 | 8.48 | 20.43% |
2016 | 7.04 | -3.98% |
2015 | 7.33 | 18.94% |
2014 | 6.17 | -24.91% |
2013 | 8.21 | 46.54% |
2012 | 5.60 | 19.3% |
2011 | 4.70 | -12.59% |
2010 | 5.37 | 39.17% |
2009 | 3.86 | 31.67% |
2008 | 2.93 | -27.57% |
2007 | 4.05 | 72.57% |
2006 | 2.35 | -7.49% |
2005 | 2.54 | -9.75% |
2004 | 2.81 | 4.51% |
2003 | 2.69 | 48.77% |
2002 | 1.81 | -41.24% |
2001 | 3.08 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | 5.15 | 41.47% | ๐บ๐ธ USA |
Becton Dickinson BDX | 3.65 | 0.28% | ๐บ๐ธ USA |
IDEXX Laboratories IDXX | 12.2 | 236.09% | ๐บ๐ธ USA |
Illumina ILMN | 4.89 | 34.28% | ๐บ๐ธ USA |
Danaher DHR | 7.70 | 111.40% | ๐บ๐ธ USA |
PerkinElmer
PKI | 4.31 | 18.17% | ๐บ๐ธ USA |
Pacific Biosciences
PACB | 4.97 | 36.43% | ๐บ๐ธ USA |
Meridian Bioscience VIVO | 4.47 | 22.70% | ๐บ๐ธ USA |